The Medical Letter on Drugs and Therapeutics
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
Prostate Cancer Screening

The US Preventive Services Task Force (USPSTF) has recently concluded that available evidence is insufficient to assess the balance between potential benefits and harms of using the prostate-specific antigen (PSA) to screen men <75 years old for prostate cancer and has recommended against screening men >75 years old.1 The median age of death from prostate cancer is 80.

Other professional organizations including the American Urological Association,2 the American Cancer Society,3 and the National Comprehensive Cancer Network (NCCN)4 recommend offering annual PSA screening to men >50 years old for those at average risk, and to younger men who are African-American or have risk factors such as a family history of the disease. The NCCN recommends obtaining a baseline PSA at age 40, beginning annual screening at age 50 and considering a prostate biopsy ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1298
 Downloadable, electronic issue - $45

Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian